Table 2.

Biologics currently available for severe asthma in pediatric age with the relative approved age of use, molecular target, and dosage.

Biological Drug	Molecular Target	Approved Age for Use	Indication	Administration Dose for Asthma
Omalizumab	IgE	≥6 years	Severe allergic asthma	0.016 mg/kg/IgE (I.U./mL) every 2–4 w°
Mepolizumab	IL5	≥6 years	Severe eosinophilic asthma	6–11 y#, <40 Kg: 40 mg every 4 w >12 y, >40 Kg: 100 mg every 4 w
Benralizumab	IL 5Rα	≥12 years (USA)	Severe eosinophilic asthma	30 mg every 4 w for the first three doses, every 8 w afterwards
Dupilumab	IL 4Rα	≥6 years	Severe T2-high asthma	6–11 y, 15–30 kg: 100 mg every 2 weeks or 300 mg every 4 w 6–11 y, 31–60 kg: 200 mg every 2 w or 300 mg every 4 w >12 y, >60 kg: 200 mg every 2 w
Tezepelumab	TSLP *	≥12 years	Severe asthma	210 mg every 4 w

* Anti-circulating thymic stromal lymphopoietin, y#: years old, w°: weeks.